Worth reading
61In focus
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
16
Year-on-year change in revenue (%)Wording
Conditional
How definitive the wording is.Contents of this document
Earnings presentationFirst quarter of the fiscal year ending March 20279 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥2,404 million+16.0%
Operating profit¥290 million+74.0%
Net income¥191 million+112.0%
Operating profit margin12 %
Selling, general and administrative expenses¥1,250 million
Full-year earnings forecast
Net Sales
10,550～10,760
Operating profit
1,365～1,555
Adjusted operating profit
1,605～1,795
Profit for the period
955～1,090
EPS
90～102
Adjusted EPS
106～119
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Progress in line with planBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Change in sales¥71 million
- Change in cost ratio¥-2 million
- Change in SG&A expenses¥73 million
- Foreign exchange effects and other factors¥33 million
- Foreign exchange effects from the elimination of unrealized gains on inventories¥-24 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
- Yen/dollar¥155
- JPY/EUR¥181
- Yen/Chinese yuan¥22.5
New initiatives
- Completion of the acquisition of BioProtect
- Appointment of Brian Barry as Chief Quality Officer
- Position optimization initiatives targeting annual cost savings of ¥24 billion by FY28
Key KPIsA metric the company considers important as a management benchmark.
- Number of 510(k) clearances obtained from the FDA30 Cases or more
Segment results
Gastrointestinal endoscopy solutions
Net Sales
¥1,684 million+21.0%
Operating profit
¥386 million+113.0%
Surgical intervention
Net Sales
¥719 million+7.0%
Operating profit (loss)
¥-24 million
Medium-term management plan targets
FY29 revenue growth5% year-on-year growth
Operating margin improvementImprovement of more than 100 bps annually from FY26
EPS growth rateCAGR of more than 10% from FY26
Target fiscal yearFY29
Capital expenditures
¥217 million
Annual Dividend
¥30 per share
| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | First quarter of the fiscal year ending March 2027 |
| Net Sales | ¥2,404 million (YoY +16.0%) |
| Operating profit | ¥290 million (YoY +74.0%) |
| Net income | ¥191 million (YoY +112.0%) |
| Operating profit margin | 12 % |
| Selling, general and administrative expenses | ¥1,250 million |
| Full-year earnings forecast | Net Sales 10,550～10,760 / Operating profit 1,365～1,555 / Adjusted operating profit 1,605～1,795 / Profit for the period 955～1,090 / EPS 90～102 / Adjusted EPS 106～119 |
| Self-assessment against the plan | Progress in line with plan |
| Segment results | Gastrointestinal endoscopy solutions Net Sales ¥1,684 million (YoY +21.0%) / Operating profit ¥386 million (YoY +113.0%) / Surgical intervention Net Sales ¥719 million (YoY +7.0%) / Operating profit (loss) ¥-24 million |
| Breakdown of Factors Affecting the Change | Factors Change in sales / Amount ¥71 million, Factors Change in cost ratio / Amount ¥-2 million, Factors Change in SG&A expenses / Amount ¥73 million, Factors Foreign exchange effects and other factors / Amount ¥33 million, Factors Foreign exchange effects from the elimination of unrealized gains on inventories / Amount ¥-24 million |
| Key KPIs | Indicator name Number of 510(k) clearances obtained from the FDA / Value 30 Cases or more / Year on year against the same period last year Not disclosed |
| Assumptions Underlying the Business Outlook | Item Yen/dollar / Value ¥155, Item JPY/EUR / Value ¥181, Item Yen/Chinese yuan / Value ¥22.5 |
| Medium-term management plan targets | FY29 revenue growth 5% year-on-year growth / Operating margin improvement Improvement of more than 100 bps annually from FY26 / EPS growth rate CAGR of more than 10% from FY26 / Target fiscal year FY29 |
| Annual Dividend | ¥30 per share |
| Capital expenditures | ¥217 million |
| New initiatives | Completion of the acquisition of BioProtect, Appointment of Brian Barry as Chief Quality Officer, Position optimization initiatives targeting annual cost savings of ¥24 billion by FY28 |
Items this document does not state (14)
Ordinary incomeGross Profit MarginResults for the three months of the current quarterProgress against full-year forecastUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookFinancial targetsPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Growth in GIS across North America, Europe, Asia and Oceania, demand for EDOF scopes and gastroenterology devices, and lower research and development and personnel expenses contributed to the improvement in results. In SIS, however, FDA-related import alerts and shipment suspensions for certain products reduced revenue.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.